Addition of Bevacizumab to Vinorelbine-Platinum Combination is Efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2025 Feb 24

PMID 39991566

Authors

I-Wei Ho

Yi-Ru Tseng

Chun-Yu Liu

Yi-Fang Tsai

Chi-Cheng Huang

Ling-Ming Tseng

Ta-Chung Chao

Jiun-I Lai

Affiliations

Soon will be listed here.

Abstract

Despite rapidly improving therapeutics, challenges remain in the treatment of advanced breast cancer. Vinorelbine, a semisynthetic vinca alkaloid, is effective and well-tolerated in breast cancer treatment. The combination of vinorelbine and platinum-combination is a well-tolerated but underreported chemotherapy regimen. Bevacizumab, a VEGF-neutralizing antibody, has shown efficacy in HER2-negative metastatic breast cancer (mBC) when combined with chemotherapy. In this study we aimed to investigate the clinical and molecular effects of vinorelbine-platinum in heavily pretreated HER2-negative mBC, as well as the impact of adding bevacizumab. We conducted a retrospective study at Taipei Veterans General Hospital to evaluate the effectiveness of the vinorelbine-platinum regimen in heavily pretreated HER2-negative mBC patients from 2016 to 2020, with a portion of patients receiving additional bevacizumab. To model the molecular perturbations at a cellular level, transcriptional profiling of a triple negative breast cancer cell line treated with cisplatin-vinorelbine was done by RNA-sequencing. The cohort included 54 patients. 50% of the patients received ≥ 5 lines of systemic treatment in the metastatic setting. All the patients had received anthracyclines and taxane. In patients treated with vinorelbine-platinum combination, the median progression-free survival (PFS) and overall survival (OS) were 2.3 and 7.3 months, respectively. With bevacizumab, median PFS improved to 4.1 months. Objective response rate (ORR) and disease control rate (DCR) without bevacizumab were 11.1% and 27.7%, respectively, improving to 25% and 83.3% with bevacizumab. Adverse events occurred in 37.0% of patients, with no grade IV events reported. Transcriptional profiling revealed significant downregulation of MAPK pathway, angiogenesis, and growth factor signaling related genes. The vinorelbine-platinum regimen, particularly with bevacizumab, shows potential efficacy even in heavily pretreated HER2-negative metastatic breast cancer patients. Molecular analyses of treated cells highlight potential targets and mechanisms of action, providing a basis for future therapeutic strategies.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Bahar M, Kim H, Kim D . Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023; 8(1):455. PMC: 10725898. DOI: 10.1038/s41392-023-01705-z. View

Perez E . Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009; 8(8):2086-95. DOI: 10.1158/1535-7163.MCT-09-0366. View

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Hart L . Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022; 386(10):942-950. DOI: 10.1056/NEJMoa2114663. View

Harry J, Ormiston M . Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer. Front Oncol. 2021; 11:772305. PMC: 8678517. DOI: 10.3389/fonc.2021.772305. View

Santen R, Song R, McPherson R, Kumar R, Adam L, Jeng M . The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002; 80(2):239-56. DOI: 10.1016/s0960-0760(01)00189-3. View

Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W . The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. Breast Cancer Res Treat. 2018; 172(1):93-104. DOI: 10.1007/s10549-018-4882-z. View

Liu C, Hsieh M, Su Y, Hung C, Pei S, Liao C . Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study. J Cancer. 2021; 12(17):5355-5364. PMC: 8317530. DOI: 10.7150/jca.60682. View

Fountzilas G, Kourea H, Bobos M, Televantou D, Kotoula V, Papadimitriou C . Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res. 2011; 31(9):3007-18. View

10.

Munzone E, Regan M, Cinieri S, Montagna E, Orlando L, Shi R . Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized.... JAMA Oncol. 2023; 9(9):1267-1272. PMC: 10346502. DOI: 10.1001/jamaoncol.2023.2150. View

11.

Rugo H, Dieras V, Cortes J, Patt D, Wildiers H, OShaughnessy J . Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1. Breast Cancer Res Treat. 2020; 184(1):161-172. PMC: 7568708. DOI: 10.1007/s10549-020-05838-5. View

12.

Cortes J, OShaughnessy J, Loesch D, Blum J, Vahdat L, Petrakova K . Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377(9769):914-23. DOI: 10.1016/S0140-6736(11)60070-6. View

13.

Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J . Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020; 382(9):810-821. DOI: 10.1056/NEJMoa1910549. View

14.

Bardia A, Hurvitz S, Tolaney S, Loirat D, Punie K, Oliveira M . Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021; 384(16):1529-1541. DOI: 10.1056/NEJMoa2028485. View

15.

Kun E, Tsang Y, Ng C, Gershenson D, Wong K . MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev. 2020; 92:102137. DOI: 10.1016/j.ctrv.2020.102137. View

16.

Sun Z, Lan X, Xu S, Li S, Xi Y . Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis. BMC Cancer. 2020; 20(1):180. PMC: 7057674. DOI: 10.1186/s12885-020-6674-1. View

17.

Schmid P, Chui S, Emens L . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply. N Engl J Med. 2019; 380(10):987-988. DOI: 10.1056/NEJMc1900150. View

18.

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

19.

Marty M, Pivot X . The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer. 2008; 44(7):912-20. DOI: 10.1016/j.ejca.2008.01.005. View

20.

Huang Z, Yu P, Tang J . Characterization of Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model. Onco Targets Ther. 2020; 13:5395-5405. PMC: 7295545. DOI: 10.2147/OTT.S249756. View